Thrombotic microangiopathy: Caplacizumab accelerates resolution of acute acquired TTP

Nature Reviews Nephrology

Volumn 12, Issue 5, 2016, Pages 259-260

  Lämmle, Bernhard ^a  

^a UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; CAPLACIZUMAB; VON WILLEBRAND FACTOR CLEAVING PROTEINASE; ADAM PROTEIN;

ACUTE ACQUIRED THROMBOTIC THROMBOCYTOPENIC PURPURA; ACUTE DISEASE; ENZYME ACTIVITY; HUMAN; IMMUNOMODULATION; NOTE; PATHOGENESIS; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); THROMBOCYTE AGGREGATION; THROMBOCYTE COUNT; THROMBOTIC THROMBOCYTOPENIC PURPURA;

ADAM PROTEINS; HUMANS; PURPURA, THROMBOTIC THROMBOCYTOPENIC; THROMBOTIC MICROANGIOPATHIES;

EID: 84962074417     PISSN: 17595061     EISSN: 1759507X     Source Type: Journal    
DOI: 10.1038/nrneph.2016.47     Document Type: Note

References (9)

1. Peyvandi, F., et al. Caplacizumab for acquired thrombotic thrombocytopenic purpura. N. Engl. J. Med. 374, 511-522 (2016
2. Rock G. A., et al. Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. N. Engl. J. Med. 325, 393-397 (1991
3. Moake J. L., et al. Unusually large plasma factor VIII: von Willebrand factor multimers in chronic relapsing thrombotic thrombocytopenic purpura. N. Engl. J. Med. 307, 1432-1435 (1982
4. Furlan, M., Robles, R., & Lämmle, B. Partial purification and characterization of a protease from human plasma cleaving von Willebrand factor to fragments produced by in vivo proteolysis. Blood 87, 4223-4234 (1996
5. Levy G. G., et al. Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura. Nature 413, 488-494 (2001
6. Furlan M., et al. von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic uremic syndrome. N. Engl. J. Med. 339, 1578-1584 (1998
7. Callewaert F., et al. Evaluation of efficacy and safety of the anti-VWF nanobody ALX 0681 in a preclinical baboon model of acquired thrombotic thrombocytopenic purpura. Blood 120, 3603-3610 (2012
8. McClain R. S., et al. Plasma exchange complications in patients treated for thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: 2011-2014. Transfusion 54, 3257-3259 (2014
9. Jian C., et al. Gain of function ADAMTS13 variants that are resistant to autoantibodies against ADAMTS13 in patients with acquired thrombotic thrombocytopenic purpura. Blood 119, 3836-3843 (2012